Best of 2024: Determinants of Gout Flares

Save

Approximately 12 million US adults in the US have gout. Two recent literature reports in JAMA and Arthritis Care & Research highlight contributors to gout flares.

ICYMI: Are Emulation Trials a Fantasy?

Save

Are emulation ‘trials’ helpful, despite the biases that occur with observational data, or do they truly mimic the results of randomized controlled trials (RCTs)?

ICYMI: Say Goodbye to Methotrexate in PMR?

Save

For decades, glucocorticoids (GCs) have formed the backbone of polymyalgia rheumatica (PMR) management.

Drug-Free Remission in Giant Cell Arteritis is Uncommon

Save

ACR24: Rheumatology Roundup

Save

Join Drs. Jack Cush and Artie Kavanaugh as they review 15+ presentations and abstracts from the 2024 ACR Convergence meeting in Washington, DC.

Maximizing DMARDs to Strive for Steroid-Free Remission in RA

Save

In 1950, three scientists were awarded the Nobel Prize for their groundbreaking discovery of steroids, heralded at the time as a "miracle cure" for rheumatoid arthritis (RA).

Is Your Practice Up to Date? New Guidelines for SLE Nephritis

Save

Randomized controlled trials (RCTs) drive guidelines; guidelines drive clinical practice. Because updated guidelines lag trials by many years and dissemination of guidelines takes additional time, rheumatologists often practice “behind the data.” The 2024 ACR Guidelines for the Management of SLE Nephritis reaffirmed many of our typical practice patterns, including hydroxychloroquine for all, renin/angiotensin blockade, and favoring mycophenolate mofetil over cyclophosphamide.

Methotrexate to Prevent RA, Clear as Mud

Save

Intervention in individuals predisposed to develop RA, with a holy grail of prevention of RA, has long been a hot topic. The 4-year results of the TREAT EARLIER study, presented at Tuesday’s oral abstract session, show that methotrexate appears to prevent the development of RA in high risk ACPA- patients.

Up-front Secukinumab in PsA?

Save

We now have an absolute plethora of agents available for use in psoriatic arthritis (PsA). In contrast we have an almost complete lack of understanding of how best to optimise use of these agents – what is the right agent at the right time for the right patient. A study presented this week has given us some further information on the topic.